Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

The Use of Janus Kinase Inhibitors in Axial Spondyloarthritis: Current Insights

22 Feb 2022

Abstract excerpt

Current pharmacological treatments of axial spondyloarthritis (axSpA) are limited to non-steroidal anti-inflammatory drugs (NSAIDs) and biological agents, including TNFα inhibitors and IL-17 inhibitors. Despite the availability of these agents, many patients either fail to respond adequately, lose their initial therapeutic response over time, or develop undesirable side effects, thus highlighting the need for new...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Autoimmune and Inflammatory Disorders Research
Share to Psoriasis: Treatment and Pathogenesis
Share to Spondyloarthritis Studies and Treatments

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 35337068
DOI: 10.3390/ph15030270

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 2 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

The Use of Janus Kinase Inhibitors in Axial Spondyloarthritis: Current InsightsPMID 35337068Read ↗

A review of JAK–STAT signalling in the pathogenesis of spondyloarthritis and the role of JAK inhibitionSemantic proximity Read ↗

Nociplastic pain in axial spondyloarthritis and psoriatic arthritis: role of JAK kinases in immunopathology and therapeutic impact of JAK inhibitorsSemantic proximity Read ↗

Upadacitinib: Mechanism of action, clinical, and translational scienceSemantic proximity Read ↗

Janus kinase inhibitors: A therapeutic strategy for cancer and autoimmune diseasesSemantic proximity Read ↗

Janus kinases and signal transducers and activators of transcription: their roles in cytokine signaling, development and immunoregulation.Semantic proximity Read ↗

Recent advances in ankylosing spondylitis: understanding the disease and managementSemantic proximity Read ↗

The JAK inhibitor tofacitinib suppresses synovial JAK1-STAT signalling in rheumatoid arthritisSemantic proximity Read ↗

Developments in the scientific and clinical understanding of the spondyloarthritides.Semantic proximity Read ↗

Pathophysiology of axial spondyloarthritis: Consensus and controversies.Semantic proximity Read ↗

JAK/STAT as a Potential Therapeutic Target for Osteolytic DiseasesSemantic proximity Read ↗

Molecular Structure and Function of Janus Kinases: Implications for the Development of InhibitorsSemantic proximity Read ↗

Janus kinase inhibitor therapy for the treatment of spondyloenchondrodysplasia with immune dysregulation due to novel ACP5 variants: a multicenter study.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.